- Active, not recruiting
NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a CAR
Updated: Apr 25, 2022
NCT03302403: Phase 1 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens.
The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.
Sponsor: Kang YU
Collaborator: CARsgen Therapeutics Co., Ltd.
ClinicalTrials.gov Identifier: NCT03302403
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Click here for details on Clinicaltrials.gov
Genetic: CAR-CD19 T cell
Genetic: CAR-BCMA T cell
Genetic: CAR-GPC3 T cell
Genetic: CAR-CLD18 T cell
Drug: Fludarabine
Drug: Cyclophosphamide
703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
China, Zhejiang
First Affiliated Hospital of Wenzhou Medical University Wenzhou,
Zhejiang, China, 325000